Abstract: The current methods and compositions provide for a novel therapeutic method for treating patients diagnosed with melanoma, especially those that have become resistant to certain other therapies. Accordingly, certain aspects of the disclosure relate to a method for treating melanoma in a subject, the method comprising administering a composition comprising a ferroptosis-inducing agent or other dedifferentiated melanoma-targeting agent to the subject.

Abstract: A pharmaceutical composition and method for treating opioid overdose, opioid dependency, and xylazine exposure is disclosed, utilizing an aqueous solution of sodium chloride. This solution contains active ingredients such as naloxone and yohimbine in specific concentrations, with naloxone targeting opioid overdose and yohimbine aimed at counteracting xylazine effects. In various embodiments, additional components like tolazoline and different buffers can be included. The disclosure introduces a unique delivery system that features a capsule with a vibrating mesh atomizer for efficient administration. Specifically, for yohimbine, a dual-reservoir capsule design facilitates controlled mixing with diluents or buffers. The administration of this pharmaceutical composition can be achieved through multiple methods, including intramuscular, intravenous, and atomized routes. The atomizing device incorporates a removable cap and a resilient air bladder, ensuring effective drug delivery.

Abstract: Provided is an application of a ?-quaternary ammonium butyrate compound having formula (I) or a racemate, a stereoisomer, a geometric isomer, a tautomer, a solvate, or a feed-acceptable salt thereof in preparing an animal feed additive, the compound being added to the daily feed of animals at a certain concentration ratio, and being capable of increasing the average daily weight gain of animals under the same food intake conditions, having no significant effect on the daily feed intake of the animals, and reducing the feed-to-meat ratio. The ?-quaternary ammonium butyrate compound disclosed herein can effectively increase the rate of daily weight gain of the animals and improve the growth performance of the animals, having no side effects on the animals, being stable and safe, and improving the production efficiency of the breeding industry whilst ensuring the health of the animals.

Abstract: The present invention pertains to a process for preparing 3-hydroxy-3-methylbutyric acid (HMB) or a salt thereof, the method comprising (a) reacting isobutylene oxide with cyanide in order to obtain 3-hydroxy-3-methylbutyronitrile, and (b) hydrolyzing the 3-hydroxy-3-methylbutyronitrile obtained in step (a) in order to obtain HMB, wherein hydrolysis step (b) is performed using either at least one nitrilase enzyme or, alternatively, using a combination of enzymes, said combination comprising at least one nitrile hydratase and at least one amidase.

Abstract: The present disclosure provides stable liquid pharmaceutical formulations comprising anti-CD200 antibodies or antigen-binding fragments thereof, and articles of manufacture and kits containing the formulations. Also featured are methods of using the formulations in cancer and autoimmune therapies, and for preventing, delaying or treating cell, tissue, or organ transplant rejection.

Abstract: The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).

Abstract: Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.

Abstract: Methods are disclosed for treating and/or preventing a neurological condition, such as neural injury or neurological disorder, in a subject through metabolic regulation of mitochondria using compounds that are natural metabolites, metabolite analogs, or derivatives of natural metabolites to modulate biochemical pathways comprising succinate and/or succinate dehydrogenase, thereby reducing microglial cell and/or astrocyte activation. Compounds and related formulations are also provided to modulate the biochemical pathways comprising succinate and/or succinate dehydrogenase for reducing or inhibiting microglial cell and/or astrocyte activation.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: The present invention is a topical composition for the treatment of animals, particularly animals in pain, wherein the composition comprises an effective amount of a local anesthetic (e.g., lidocaine) and an analgesic (e.g., meloxicam).

Abstract: Compositions, methods of manufacturing compositions, methods of protecting against respiratory problems including coronavirus and coronavirus-associated severe acute respiratory syndrome (SARS) in humans and animals, are provided. Compositions comprising inorganic nitrate used for improving nitric oxide levels, improving health and/or reducing symptoms of SARS are provided. The compositions and methods are applicable for subjects experiencing SARS, and for protecting non-infected subjects against SARS. Compositions and methods for improving nitric oxide levels in a subject disclosed herein comprise administration of compositions comprising inorganic nitrate such as potassium nitrate or sodium nitrate optionally combined with ascorbate.

Abstract: Some embodiments may be of spearfishing apparatus fitted with at least one magnet configured to repel sharks away from the spearfishing apparatus. The spearfishing apparatus may be one or more of: a spearfishing shaft, a spearfishing tip, and/or a spearfishing gun. Such magnets may be electromagnets powered by batteries in some embodiments.

Abstract: Beta-hydroxybutyric acid compositions for oral delivery are substantially free of beta-hydroxybutyrate salts and are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By excluding beta-hydroxybutyrate salts (e.g., less than 1% by weight) containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid.

Abstract: Systems and methods for selecting a treatment regimen for a particular patient are provided. The treatment regimen is selected using a first data store including a first plurality of patient records for a first plurality of patients, and a second data store including efficacy rates of a plurality of treatment regimens against a plurality of infections and infection-causing pathogens. The system, or a user of the system, identifies a first infection of the particular patient and a first treatment regimen to be prescribed to treat the first infection. A second plurality of patient records is generated by identifying, in the first plurality of patient records of the first data store, patient records associated with diagnosis or treatment of the first infection. The second plurality of patient records are appended with efficacy rates for the first infection from the second data store.

Abstract: Provided is an application of a ?-quaternary ammonium butyrate compound having formula (I) or a racemate, a stereoisomer, a tautomer, a solvate, or a feed-acceptable salt thereof in preparing an animal feed additive, the compound being added to the daily feed of animals at a certain concentration ratio, and being capable of increasing the average daily weight gain of animals under the same food intake conditions, having no significant effect on the daily feed intake of the animals, and reducing the feed-to-meat ratio. The ?-quaternary ammonium butyrate compound can effectively increase the rate of daily weight gain of the animals and improve the growth performance of the animals, having no side effects on the animals, being stable and safe, and improving the production efficiency of the breeding industry whilst ensuring the health of the animals.

Abstract: The present invention is for an acidic cleaning composition which has excellent cleaning performance, low toxicity and good antimicrobial efficacy. The inventive acidic cleaning compositions are capable of sanitizing or disinfecting a variety of hard surfaces. The inventive acidic cleaning compositions can take a variety of forms, such as: disinfecting wipes, all-purpose disinfecting sprays, kitchen cleaners, bathroom cleaners, toilet cleaners, etc. The inventive acidic cleaning compositions have good cleaning properties and low residue.

Abstract: Liquid thickener compositions are provided. The compositions may be used to thicken foods and other products. The compositions include at least one gum or thickener and one or more hydration or swelling inhibitors. The inhibitors decrease the viscosity of the concentrated thickener composition, but then permit the composition to function as a thickener upon dilution. Such compositions may provide for thickener compositions that are readily flowable and that require decreased mixing compared to other thickener compositions.

Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

Abstract: The invention provides methods for reducing the percentage of body fat, increasing the level of adiponectin, and/or treating or reducing the risk of cardiovascular disease (CVD) and coronary heart disease (CHD). Such methods include administering to an animal or human sufficient levels of a compound comprising a tri blend of HPMC (K15, K100, and K200) and myristic fatty acid.

Abstract: Methods and systems for temperature-controlled, on-site generation of peracids, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions are disclosed. In particular, methods for using an adjustable biocide formulator or generator system overcome the limitations of temperature on the kinetics of the peracid generation and/or peracid decomposition inside an adjustable biocide formulator or generator system. The methods include the controlling of the temperature of at least one raw starting material, namely water, to improve upon methods of on-site generation of peracids. The methods allow for the generation of user-selected chemistry without regard to the ambient temperatures of the raw starting materials and/or the biocide formulator or generator system.

Abstract: Pharmaceutical or food supplement preparation including alpha-lactalbumin and at least one short-chain fatty acid (SCFA) or a precursor or derivative thereof for use in the treatment of disorders of the central nervous system; the SCFA or its precursor or derivative may be contained in at least one first dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint and the alpha-lactalbumin in at least one second dosage unit together with a carrier acceptable from the pharmaceutical or food standpoint, and said dosage units may be distinct units intended for simultaneous or separate administration or the preparation may consist of a pharmaceutical or food supplement composition comprising the at least one short-chain fatty acid or a precursor or derivative thereof and alpha-lactalbumin together with a carrier acceptable from the pharmaceutical or food standpoint.

Abstract: The present invention provides thin-film forming compositions comprising an antiseptic (e.g., povidone iodine, chlorhexidine, or octenidine), a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the composition yields a continuous and flexible protective film upon substantial removal of the solvent. The compositions are useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as for prevention of such infections in appropriate clinical settings (e.g., as liquid bandages or dressings). Additionally, the compositions of this invention are also useful for the treatment of infections and as a disinfectant skin preparation for pre- and/or post-surgical operations.

Abstract: The present invention relates to glycolic acid or a pharmaceutically acceptable salt or ester thereof for use in the treatment or prevention of ischemic damage. In a preferred embodiment the present invention relates to a method for decreasing cell death caused by an ischemic insult comprising contacting glycolic acid or a pharmaceutically acceptable salt or ester thereof with hypoxic tissue, in particular cortical neurons or myocardial tissue.

Abstract: Ketogenic compositions include a racemic or near racemic mixture of R- and S-beta-hydroxybutyric acids and a racemic or near racemic mixture of R- and S-beta-hydroxybutyrate salts. The R-enantiomer elevates ketone bodies and increases the rate at which ketosis is achieved. Including an equivalent or near equivalent amount of the S-enantiomer to provide alternative benefits. The R- and S-beta-hydroxybutyric acids are more rapidly absorbed and utilized by the body than salts or esters, enhance taste, and reduce the need to include other edible acids. The R- and S-beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. The composition may contain a dietetically or pharmaceutically acceptable carrier and a racemic or near racemic mixture of R- and S-beta-hydroxybutyrate salts and acids. The composition contains <100% by molar equivalents of total R,S-beta-hydroxybutyrate salts and >0% by molar equivalents of R,S-beta-hydroxybutyric acids.

Abstract: The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and genetic disorders affecting the creatine kinase system comprising administering creatine prodrugs or pharmaceutical compositions thereof. The invention also describes treating a genetic disease affecting the creatine kinase system, such as, for example, a creatine transporter disorder or a creatine synthesis disorder comprising administering creatine prodrugs or pharmaceutical compositions thereof.

Abstract: Disclosed herein are compositions and methods for the treatment of conditions induced by chronic inflammation. According to some embodiments, the compositions and methods involve the use of metformin and sodium butyrate in the treatment of conditions induced by chronic inflammation.

Abstract: An antimicrobial composition containing a synergistic combination of an imidazole antifungal agent and activated creatinine is provided, wherein the imidazole antifungal agent represents in the range of about 0.5 mol % to about 30 mol % of the combination of the antifungal agent and the activated creatinine in the composition. Methods for treating bacterial infections, fungal infections, viral infections, and wounds are also provided, as are other methods of use, including methods for disinfecting inert surfaces, methods for preserving food products, and methods for treating plants. In addition, the invention provides a method for enhancing the antifungal effect of an imidazole antifungal agent as well as a method for enhancing the antibacterial effect of activated creatinine. Compositions and methods involving use of activated 2-amino-imidazol-4-one analogs other than activated creatinine are also provided.

Abstract: The present invention provides a method of administering magnesium threonate to a subject in need of supplementing magnesium. At least a portion of magnesium (Mg) and threonate (T) is present in a salt form of MgT2. The method may comprise administration of magnesium threonate at two different time points per day. The method may comprise administering, at a first time point, a first oral dosage form comprising magnesium threonate. The method may comprise administering, at a second time point, a combination of the first oral dosage form and a second oral dosage form comprising magnesium threonate. The first and second oral dosage forms may exhibit different dissolution profiles in a dissolution medium.

Abstract: Methods for modifying neuronal functional activity and/or treating a neurological disorder by using agents that raise neuronal intracellular concentration of magnesium are disclosed. Also provided herein are methods of determining the amenability of an individual to treatment for a neurological disorder, by measuring changes in intracellular magnesium concentration.

Abstract: The compounds of the present invention are represented by the following compounds having Formula (I) and Formula (I?): where the substituents R, R1, R3 R4, R?, W, X, Y, Z, k, and m are as defined herein and where the substituents R, R1, R2, R3, R4, X, Y, Z, and m are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Ketogenic compositions include a mixture of optically pure S-beta-hydroxybutyrate salts and acid(s) or non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contains from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.

Abstract: An anti-inflammatory and anti-oxidative nutraceutical composition containing C60 fullerene, a COX-2 inhibitor, and a medium chain triglyceride. The combined use of C60 and COX-2 inhibitor has unexpected benefits in promoting health, including synergistic effects in fighting cancer, slowing aging, and in some cases, reversing aging. Advantageously, Nigella sativa (“black seed”) oil is used to provide both medium chain triglycerides and COX-2 inhibitors.

Abstract: The present invention provides an adhesive, high water content gel that does not cause a heat generation problem even when used as a patient plate for electrosurgical units through which high current flows and that is excellent in adhesion, as well as an electrode pad including the gel. The present invention relates to an adhesive, high water content hydrogel containing a polymer matrix that includes a copolymer of a polymerizable monomer and a crosslinkable monomer, water, a polyhydric alcohol, an electrolyte, polyacrylic acid, and polyvinyl alcohol, the hydrogel containing, based on 100% by weight of the total hydrogel, 40-70% by weight of water, 1.0-5.0% by weight of polyacrylic acid, and 0.5-5.0% by weight of polyvinyl alcohol, and being produced by copolymerization. An electrode pad is also obtained by coating a conductive layer formed on a base film with the adhesive, high water content hydrogel.

Abstract: A pesticide formulation preserves an effective concentration of an active form over time. For example, the active form may be generated over time as it is removed from the system. For example, Calcium Formate may be transformed to an active form of Formic Acid. For example, modulator such as citric acid may facilitate driving the generative reaction forward, for example by removing Calcium form the solution. Optionally Boric acid may be added to the formulation. The formulation may be applied dry and/or wet to the organisms and/or their living space.

Abstract: Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.

Abstract: Some embodiments may be of spearfishing apparatus fitted with at least one magnet configured to repel sharks away from the spearfishing apparatus. The spearfishing apparatus may be one or more of: a spearfishing shaft, a spearfishing tip, and/or a spearfishing gun. Some embodiments may be of personal floatation devices (PFDs) fitted with at least one magnet configured to repel sharks away from the PFDs. Some PFDs may be fitted with a tethered drop-down magnetic apparatus to protect lower extremities of a wearer of such PFDs. Such magnets may be electromagnets powered by batteries in some embodiments.

Abstract: The invention relates to compositions and methods that include short chain fatty acids (SCFAs), related therapeutic compounds, and other compounds, including combinations thereof, for the treatment or prevention of diseases or disorders.

Abstract: Provided is an antimicrobial composition comprised of at least one degradation product of oxidized cellulose (OC), such as oxidized regenerate cellulose (ORC), and minocycline, methods of preparation thereof and uses thereof.

Abstract: The present disclosure provides, in one embodiment, a method of treating or preventing an ID2 protein-related disease in a patient at risk of developing or having such a disease by administering to the patient a composition in an amount and for a time sufficient to increase degradation of HIF? in a cell affected by the ID2 protein-related disease in the patent and/or to decrease half-life of HIF? in the cell affected by the ID2 protein-related disease in the patient, as compared to an untreated cell affected by the ID2 protein-related disease.

Abstract: A countermass liquid for a shoulder launched propulsion system that has low corrosivity, high density, low viscosity, and a constant viscosity as a function of temperature. Upon function of the shoulder launched propulsion system, the countermass liquid may be expelled through the breach end of the shoulder launched propulsion system by expanding propellant gas. The countermass liquid may be an organic salt selected from the group consisting of at least one or more of cesium formate and potassium formate.

Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.

Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.

Abstract: Beta-hydroxybutyrate (BHB) mixed salts are formulated to induce or sustain ketosis in a subject. The BHB mixed salts provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. BHB mixed salt compositions include two, three or four of sodium BHB, potassium BHB, calcium BHB, or magnesium BHB. BHB mixed salt compositions include R-BHB and/or S-BHB, such as enriched with either R-BHB or S-BHB. BHB mixed salt compositions may include BHB mixed salts and beta-hydroxybutyric acid. BHB mixed salts may be provided as or mixed with a dietetically or pharmaceutically acceptable carrier. BHB mixed salt compositions can be a solid, such as a powder, or a liquid, such as a beverage. A mixed salt-acid composition is particularly well-suited for flavored beverages.

Abstract: The present invention relates to a pharmaceutical composition or a kit comprising, a first substance capable of raising intracellular cAMP levels, and a second substance capable of modulating intracellular calcium concentration. Likewise, the present invention relates to methods of treating patients suffering from autism spectrum disorder (ASD) phenotype 1 by administering an effective amount of a substance capable of raising intracellular cAMP levels and, optionally, an effective amount of a substance capable of modulating intracellular calcium concentration.

Abstract: The present invention relates generally to methods for forming peroxyformic acid, comprising contacting formic acid with hydrogen peroxide. The methods for forming peroxyformic acid can include adding formic acid with a relatively lower concentration of hydrogen peroxide, or adding formic acid to a peroxycarboxylic acid composition or forming composition to react with hydrogen peroxide in the compositions. The present invention also relates to peroxyformic acid formed by the above methods. The present invention further relates to the uses of peroxyformic acid for treating a variety of targets, e.g., target water, including target water used in connection with oil- and gas-field operations. The present invention further relates to methods for reducing or removing H2S or iron sulfide in the treated water source, improving clarity of the treated water source, or reducing the total dissolved oxygen or corrosion in the treated water source, using peroxyformic acid, including peroxyformic acid generated in situ.

Abstract: An object of this invention is to provide a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction, and a composition for ameliorating learning disorders. Provided is a composition comprising a combination of a TRH analog and arundic acid.

Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to enhance or promote lipolysis, increase adipocyte fat oxidation, induce adipocyte and muscle mitochondrial biogenesis, increase energy expenditure, decrease total body weight and increase body fat loss.

Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Abstract: The present invention concerns a pharmaceutical composition comprising formic acid and at least one C1-C4 alkyl ester of lactic acid, malic acid, tartaric acid, citric acid, preferably ethyl lactate, for the topical treatment of warts.

Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and survival of animal offspring.